CT
NVO

Cambridge Trust’s Novo Nordisk NVO Stock Holding History

Cambridge Trust’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$13M Hold
100,857
– – 0.49% 64
2023
Q4 		$10.4M Buy
100,857
+525
+0.5% +$51.9K 0.43% 67
2023
Q3 		$9.12M Sell
100,332
-9,914
-9% -$873K 0.42% 67
2023
Q2 		$8.92M Hold
110,246
– – 0.4% 65
2023
Q1 		$8.77M Hold
110,246
– – 0.42% 62
2022
Q4 		$7.46M Hold
110,246
– – 0.33% 71
2022
Q3 		$5.49M Sell
110,246
-2,200
-2% -$118K 0.26% 82
2022
Q2 		$6.26M Sell
112,446
-886
-0.8% -$49.2K 0.27% 82
2022
Q1 		$6.29M Sell
113,332
-146
-0.1% -$7.49K 0.22% 91
2021
Q4 		$6.35M Buy
+113,478
New +$6.15M 0.2% 94
2016
Q4 		– Sell
-12,072
Closed -$251K – 269
2016
Q3 		$251K Sell
12,072
-186
-2% -$4.61K 0.02% 229
2016
Q2 		$330K Buy
+12,258
New +$336K 0.03% 201

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cambridge Trust's NVO Position: Q1 2024 in Review

Cambridge Trust held its Novo Nordisk (NVO) position steady in Q1 2024 at 100,857 shares worth $13M. The position accounts for 0.49% of the portfolio, ranked #64.

Cambridge Trust first reported a position in NVO in Q2 2016 and has held it in 12 quarters since. 1,744 funds tracked by Wall St. Rank hold NVO as of Q1 2024.

  • Cambridge Trust held 100,857 shares of Novo Nordisk worth $13M as of Q1 2024.
  • Cambridge Trust left its Novo Nordisk share count unchanged in Q1 2024.
  • Novo Nordisk made up 0.49% of Cambridge Trust's portfolio in Q1 2024, its #64 holding.
  • Cambridge Trust first reported a position in Novo Nordisk in Q2 2016 and has held it in 12 quarters since.
  • 1,744 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.